In Search of Effective Anticancer Agents—Novel Sugar Esters Based on Polyhydroxyalkanoate Monomers

Wojciech Snoch 1, Dawid Wnuk 2, Tomasz Witko 1, Jakub Staroń 3, Andrzej J. Bojarski 3, Ewelina Jarek 1, Francisco J. Plou 4 and Maciej Guzik 1,*

Abstract: Cancer is one of the deadliest illnesses globally. Searching for new solutions in cancer treatments is essential because commonly used mixed, targeted and personalized therapies are sometimes not sufficient or are too expensive for common patients. Sugar fatty acid esters (SFAEs) are already well-known as promising candidates for an alternative medical tool. The manuscript brings the reader closer to methods of obtaining various SFAEs using combined biological, chemical and enzymatic methods. It presents how modification of SFAE’s hydrophobic chains can influence their cytotoxicity against human skin melanoma and prostate cancer cell lines. The compound’s cytotoxicity was determined by an MTT assay, which followed an assessment of SFAEs’ potential metastatic properties in concentrations below IC_{50} values. Despite relatively high IC_{50} values (63.3–1737.6 µM) of the newly synthesized SFAE, they can compete with other sugar esters already described in the literature. The chosen bioactives caused low polymerization of microtubules and the depolymerization of actin filaments in nontoxic levels, which suggest an apoptotic rather than metastatic process. Altogether, cancer cells showed no propensity for metastasis after treating them with SFAE. They confirmed that lactose-based compounds seem the most promising surfactants among tested sugar esters. This manuscript creates a benchmark for creation of novel anticancer agents based on 3-hydroxylated fatty acids of bacterial origin.

Keywords: anticancer agents; sugar esters; polyhydroxyalkanoates; fluorination; chemical modifications; melanoma; prostate cancer

1. Introduction

According to statistics provided by the World Human Organization, cancer is one of the deadliest illnesses globally. It is estimated that it caused 9.6 million deaths, or one in six deaths, in 2018. Lung, prostate, colorectal, stomach and liver cancers are the most common types of cancer in men, while breast, colorectal, lung, cervical and thyroid cancers are the most common among women [1]. Based on ‘Cancer Treatment and Survivorship Statistics, 2019’, the most prevalent cancers in 2019 in the USA were prostate (3,650,030), colon and rectum (776,120), skin melanoma (684,470) among males and breast (3,861,520), uterine corpus (807,860), and colon and rectum (768,650) among females [2]. Moreover, prostate cancer was the fifth most common cancer in Europe in 2018 (450,000) [3]. These statistics bring us to conclusions that searching for new solutions in melanoma and prostate cancer treatment is still essential.
Nowadays, mixed, targeted and personalized therapies are becoming more commonly used to treat cancer [2]. Many of them are combinations of surgery and radio-, chemo-, immune-, photo-, thermo- and cryotherapies. Some medicines disrupt cell division by interfering with the cell’s cytoskeleton (tubulin, mitotic spindle). Others interact with the DNA (e.g., cis-Pt, doxorubicin, fluorouracil) [4,5] of the cells or even disturb signalization by interacting with transmembrane hub proteins to drive the cell to apoptosis [6]. On the other hand, the most prospective therapies are inspired by nature itself: these are either based on monoclonal antibodies or programmed bacterial pathogens specifically targeting tumor cells within a host body [7]. In spite of the wide range and high effectiveness of the mentioned therapies, sometimes even they are not sufficient. Moreover, very often they are too expensive for common patients. Therefore, our attention was drawn to other tools that could both reduce the doses of drugs and the amount of drugs used in a given mixed, targeted therapy. The properties of sugar fatty acids esters (SFAE) make them promising candidates to be another valuable tool [8,9].

SFAEs are compounds widely used in the cosmetics and food industries because their antifungal and antibacterial properties. The physiochemistry of these surfactants allows for the formation of micelles or emulsions, which extends their applicability also to the pharmaceutical industry [10–12]. It has been shown that SFAE molecules are able to block glycolysis [13]. On the other hand, fatty acid chains of SFAE may cause their non-specific anchorage in cell membranes, consequently leading to the damage of transmembrane proteins, leakage of valuable substances outside of the cell and penetration of the unfavorable ones [14]. This aspect is widely discussed in the literature on the example of the influence of SFAE on microorganisms: Bacillus sp., Staphylococcus sp., Escherichia sp., Salmonella sp. or Listeria sp. [12–14]. However, activity of these surfactants may be different while investigated on mammalian cells biology [15].

In 1970s scientists began research on anti-cancer properties of SFAE [16]. The experiments carried out on both in vitro and in vivo cell models confirm that SFAE may inhibit the secretion of TNF-α and some proinflammatory cytokines such as IL-1B, IL-6 and IL-8 [17]. Moreover, their ability to inhibit in vitro excessive proliferation of bone marrow cells in the acute myelogenous leukemia model was also described [18]. It has also been shown that biological activity of SFAE may depend on the length of an aliphatic chain and their number in the whole ester molecule (mono- vs. di- vs. tri-/poly-esters). Furthermore, the type of sugar that builds SFAE plays a significant impact on their properties, affecting the hydrophilic–lipophilic balance (HLB) and thus the physical properties of the whole ester (solubility, micelles formation, stabilization of emulsion systems) [15].

The biological activity of SFAEs can also be altered by their structural modifications [19]. The literature reports that the biological activity of commonly used anti-cancer drugs can be improved through the introduction of halides, and a similar strategy can also be applied to sugar esters [20]. The most commonly used in pharmacology, and simultaneously, the most promising modifications of moieties in terms of their antiproliferative properties are perfluorination [21], chlorination [22], bromination [23] and the introduction of halogenated alkyl (trifluoromethyl, pentafluoroethyl) [24] and fluorophenyl [25] or trimethoxyphenyl [26] groups. They can be obtained by the substitution of hydrogen atoms in the carbon chain or hydroxyl groups of a sugar for halide atoms into the molecular structure. As the literature reports, the cytotoxicity of the modified molecules may be changed significantly both by the number and the location of the introduced halides. For example, substitution of all carbon atoms with 6–19 fluorine atoms in the hydrophobic part of SFAE showed promising anticancer potential. However, these compounds were also highly toxic to normal cells [27]. Therefore, it is essential to pay attention to increasing selectivity towards cancer cells without harming the native ones during the drug designing process.

Here, we propose the use of bacterially derived natural monomers, namely (R)-3-hydroxyacids originating from polyhydroxyalkanoates polymers (PHA), as a basis for the synthesis of modified SFAE (Figure 1). PHAs can serve as material for manufacturing of nontoxic implants and other medical devices. They are also often used as media for drug
delivery upon implantation [28–30]. To date, more than 150 different (R)-3-hydroxyacids have been reported, thus creating endless possibilities for further modifications [31]. Despite the differences, all of them share two unchanging features—a presence of carboxylic and a β-carbon-located hydroxyl groups. The first one enables the synthesis of a wide range of SFAEs, the latter, on the other hand, enables the introduction of various moieties into the SFAE molecule. Recently, we have reported routes towards synthesis of (R)-3-hydroxyacid-based glucose esters with fluorine modified analogues [29]. Here, we expanded the glucose esters library with galactose and lactose SFAE versions and tested the whole collection of compounds against human melanoma and prostate cancer cells in vitro. In this paper, we present the description on biocatalytic synthesis of novel SFAEs and their structural characterization by infrared and NMR spectroscopies combined with mass spectrometry analysis. Furthermore, we demonstrate a set of biological studies elucidating sugar esters’ biological potential. Firstly, the cytotoxicity of these novel compounds was examined, together with their metastatic properties, in concentrations below IC$_{50}$. The results were compared to sugar esters from literature and some compounds commonly used in clinical oncology.

![Figure 1. Scheme of sugar fatty acid esters enzymatic synthesis with glucose as an example. The remaining sugar-based SFAEs (galactose and lactose) and all structures of the obtained compounds are presented in Supplementary Figure S1. Where: R$_1$: -OH group or nonanoic acid—structure shown in blue rectangle; R$_2$: modified or not modified (mPHN or F-mPHN) PHN monomeric residues—their structures are shown in red rectangle; R$_3$: -OH group or one of residues which structures are shown in red rectangle.](image)

**2. Materials and Methods**

2.1. Preparation of Unmodified and Modified Polyhydroxynonanoate Monomers

Polyhydroxynonanoate (PHN) was produced using *Pseudomonas putida* KT2440 in a controlled continuous fermentation process as described previously [30]. Briefly, nonanoic acid was used as a source of carbon and energy for bacteria. The polymer was extracted with ethyl acetate and characterized as described in Sofinska et al. [30]. Next, it was decomposed to monomers through acidic methanolation. The hydroxylated acid methyl esters were analyzed by gas chromatography. Modification of the resultant methyl esters of monomers was conducted as described previously [29]. The obtained monomers were converted into their acidic forms using *Candida antarctica* lipase B under aqueous conditions to obtain sodium salts.
2.2. Synthesis of Sugar Fatty Acid Esters (SFAE)

Enzymatic reactions were performed in 2-methyl-2-butanol (2M2B). Sugar substrates: lactose, glucose and galactose were supplemented with solvent and the remaining reagents, giving 20 mg mL\(^{-1}\) (2 molar equivalents) of final concentration in a reactor. The remaining substrates were: nonanoic acid methyl esters (C9) 6.04 mg mL\(^{-1}\) PHN monomer methyl esters 9.48 mg mL\(^{-1}\) and fluorinated PHN methyl esters 9.48 mg mL\(^{-1}\) (up to 1 molar equivalent), respectively. Additionally, 100 mg mL\(^{-1}\) of activated molecular sieves (4 Å) were added to maintain anhydrous conditions. The reactions were initiated by the addition of 40 mg mL\(^{-1}\) catalyst: enzyme Novozym \textit{Candida antarctica} lipase B (CalB) and conducted at 55 °C for 48 h with shaking (240 rpm; New Brunswick™ Scientific Exella E 24 Incubator Shaker Series, Eppendorf, Hamburg, Germany).

2.3. HPLC Analysis

Analyses were performed using UHPLC measurements in Agilent 1290 Infinity system with automatic autosampler (Santa Clara, CA, USA) and MS Agilent 6460 Triple Quad Detector (Agilent, Singapore) equipped with Zorbax Eclipse Plus 300SB-C18 Agilent column (2.1 mm x 50 mm, 1.8 µm, Santa Clara, CA, USA). To separate the components of the reaction mixture, the column was eluted at 30 °C at a flow rate of 0.4 mL min\(^{-1}\) and developed with a gradient of elution of solvent A (water) and solvent B (methanol) as follows: 0.00 min (95% A/5% B) to 1.00 min (100% B) to 4.50 min (95% A/5% B) to 5.00 min (95% A/5% B). The interval between injections was 4.5 min. MS Agilent 6460 Triple Quad tandem mass spectrometer with Agilent Jet Stream Electrospray (ESI) interface was used in negative ion mode. Nitrogen with a flow rate of 10 L min\(^{-1}\) was used as a drying and collision gas. The drying gas temperature was set to 350 °C and the shielding gas temperature to 200 °C. The capillary voltage was set to 4000 V and the nozzle voltage to 2000 V. All compounds were monitored in scanning mode and product ions with different collision energies (5-30 eV) (m/z products in Table S1 in Supplementary Materials). Workstation MassHunter Data Acquisition 1.1 version was used to control the HPLC-MS data collection and processing.

2.4. Preparative HPLC

Preparative scale liquid chromatography was used to purify SFAE products. The crude reaction mixture was purified on VersaPack™ C18 (SUPELCO Analytical, Bellefonte, PA, USA) preparative column in the MeOH/H\(_2\)O system with an increasing MeOH gradient of 50 to 100%. The elution of the reagents was monitored with TLC chromatography performed on C18 Merck silica gel plates (with the same elution system as in preparative separation) and high performance liquid chromatography coupled to mass spectrometer: Waters TQD instrument in scan mode ESI: +100–1000 m/z.

2.5. \(^1\)H NMR and \(^{19}\)F NMR Spectroscopy

Twenty mg samples of each compound were dried under vacuum. Samples were analyzed on Bruker (BioSpin GmBH, Rheinstetten, Germany) in CDCl₃.

2.6. IR Spectroscopy

The compounds tested were dissolved in methanol. All spectra were collected by using IR microscope Nicolet iN10 (Thermo Scientific™ part of Thermo Fisher Scientific, Madison, USA). All reflection measurements were performed on gold layer by using high-sensitivity MCT-A detector within spectral range from 4000 cm\(^{-1}\) to 675 cm\(^{-1}\), 128 scans during 25 s with normal resolution just after the solvent evaporation or immediately after application in case of volatile substances. Fully automated adjustable aperture for measuring field extraction was 150 µm x 150 µm.
2.7. Cell Cultures

The following cell lines were used: human prostate cancer cells from metastases to the brain DU145 (ATCC® HTB-81™, Manassas, Virginia); healthy human prostate epithelial cell line as a control (PNT2; Sigma-Aldrich, Darmstadt, Germany); human melanoma Hs 294T (ATCC® HTB-140™, Manassas, Virginia); human epidermal keratinocytes (HaCaT HEK001 (ATCC® CRL-2404™, Manassas, Virginia); and normal human skin fibroblasts BJ (ATCC® CRL2522™) as controls. The cells were cultured in 37 °C with humidified atmosphere enriched with 5% CO₂ in appropriate cell culture media: DMEM F12Ham (Sigma-Aldrich, Darmstadt, Germany) + 5% FBS (Thermo Fisher Scientific; Gibco; Waltham, MA, USA); RPMI-1640 (Sigma-Aldrich, Darmstadt, Germany) + 10% FBS (Thermo Fisher Scientific; Gibco; Waltham, MA, USA); DMEM high glucose (Sigma-Aldrich) + 10% FBS (Thermo Fisher Scientific; Gibco; Waltham, MA, USA); DMEM low glucose (Sigma-Aldrich, Darmstadt, Germany) + 10% FBS (Thermo Fisher Scientific; Gibco; Waltham, MA, USA). All media contained a penicillin/streptomycin (Sigma-Aldrich, Darmstadt, Germany) cocktail.

2.8. MTT Cytotoxicity Assay

For the determination of the cytotoxic effect of tested compounds, normal (control) and cancer cell lines cells were tested at a concentration of $2.5 \times 10^4$ cells cm$^{-2}$ in appropriate culture medium into 96 well microplates (VWR, Radnor, PA, USA). Cells were preincubated with four different concentrations of tested compounds: 0.5, 0.25, 0.125 and 0.0625 mg mL$^{-1}$ for 24 h, 72 h and 120 h in cell incubator. After the incubation, MTT labelling reagent (final concentration 0.5 mg mL$^{-1}$) and solubilizing solution were added according to the protocol. The samples absorbance was measured using a microplate reader (Multiscan FC; Thermo Fisher Scientific, Waltham, MA, USA) by 570 nm wavelength, 620 nm for reference.

2.9. Fluorescent Staining

Cellular studies 12-well plates were used, cell density $3 \times 10^5$ per well. After 24 h and 48 h of incubation with tested compounds (0.0625 mg mL$^{-1}$), the samples were fixed according to standard protocol. Tubulin (green; AlexaFluor-488 mouse anti-β-tubulin IgG; BD Biosciences, San Jose, CA, USA, Pharminogen; cat. 558605), vimentin (infra-red; I: rabbit-anti-vimentin IgG; GeneTex, Irvine, CA, USA; GTX100619; II: chicken-anti-rabbit-AlexaFluor647 IgG; ThermoFisher, Waltham, MA, USA) and counterstained nuclei (blue; Hoechst 33258; Sigma-Aldrich, Darmstadt, Germany) and F-actin (red; AlexaFluor546-phalloidin; ThermoFisher, Waltham, MA, USA). Next, the samples were washed 5 times with deionized water and prepared for imaging with Fluorescent Mounting Medium (Dako Omnis, Agilent, Santa Clara, CA, USA).

2.10. Transmigration Assay

Transmigration assay was performed using 24-well glass-bottom plate (Eppendorf) containing microporous membranes in Boyden’s chamber (Corning; pore diameter: 8 µm; membrane diameter: 6.5 mm). Native DU145 and HTB140 cells were seeded at density of $3 \times 10^5$ cells per membrane with tested compounds (0.0625 mg mL$^{-1}$) and left for 48 and 96 h for transmigration. The transmigrating cells were fixed with 3.7% formaldehyde and counted. The result is presented as a reference to the rate of cell proliferation in the corresponding compound.

2.11. Cell Structures Imaging

Microscopic measurements and observations were carried out with the use of fluorescent techniques performed on Zeiss Axio Observer Z.1 microscope with LSM 710 module (Carl Zeiss Microscopy GmbH Carl-Zeiss-Promenade 10, 07745 Jena, Germany). Image acquisition, processing, deconvolution and analysis were performed using Zeiss ZEN Black software ver. 8.1.0.484 and FluoRender 2.21.0. An oil immersion 40×/NA:1.4 lens was used for observations. Parameters used for acquisition of cell morphology were: nucleus—blue
channel (405 nm); microtubular network—green channel (488 nm); Actin—red channel (546 nm); vimentin—far red channel (647 nm).

3. Results

3.1. Synthesis and Modification of Polyhydroxynonanoate Monomers (mPHN)

The process of bacterial polyhydroxynonanoate (PHN) synthesis provided 130 g L\(^{-1}\) of dry biomass, which after extraction, purification and filtration, gave the desired polymer with 71% efficiency. Its composition was analyzed using gas chromatography and revealed that the PHN polymer consisted of 77.7% (R)-3-hydroxynonate (R3OH-C9) and 22.3% (R)-3-hydroxyheptane (R3OH-C7) monomeric units. A portion of that mixture was subjected to further chemical modification. The weighed, purified and dried post-reaction mixture contained fluorinated methyl esters of mPHN monomers (mPHN-Me) (C7 and C9 chains). The actual conversion of 48.5% was determined from the average expected mass for the reaction, whose theoretical efficiency is 100%. Samples were submitted to \(^1\)H and \(^{19}\)F NMR analyses, which confirmed the structural modification of the PHN (R)-3-hydroxyacids and the synthesis of the (R)-3-(2,2,2-trifluoroethoxy) nonanoic acid (R)-3-(2,2,2-trifluoroethoxy) heptanoic acids (together called F-mPHN-Me, Figure S1 in Supplementary Materials). The infrared spectroscopic observation further confirmed the successful synthesis of the fluorinated compounds. The spectra of purified samples after reacting mPHN-Me with trifluoroethyl trifluoromethanosulphonate revealed the disappearance of stretching vibrations in the range 3000–3500 cm\(^{-1}\) characteristic for free hydroxylic group. Moreover, the appearance of new peaks was observed (1465.1 cm\(^{-1}\), 1377 cm\(^{-1}\), 1261 cm\(^{-1}\)), which correspond to -CF\(_3\) groups connected to the alkyl chain of the monomers. A similar pattern was observed by Li et al., who analyzed the infrared substrate spectrum of CF\(_3\)-CH\(_2\)-O-CH\(_3\) molecules (described and discussed in detail in the Supplementary Materials).

3.2. Structural Analysis of Synthesized Sugar Esters

A library of sugar esters of both nonanoic acid and (R)-3-hydroxyacids derivatives was created by a biocatalytic approach employing immobilized Candida antarctica lipase B (CalB). In addition, a series of SFAEs with aliphatic, nonanoic and heptanoic hydrophobic tails were generated as controls to all further performed experiments. The structures of the sugar esters were confirmed by \(^1\)H NMR and IR analyses (Figures S4–S12 in Supplementary Materials). In general, it was observed that signals between 5.25 and 0.75 ppm, originated from newly synthesized fatty acid-sugar ester, consisted of several multiplets. Signals between 1.5 and 0.75 correspond to fatty acid chains, shifts between 2.25 and 5.25 came from sugar \(^1\)H signals, and multiplets around 4.5 and 4.0 came from \(^1\)H localized on a nearby ester bond. The differences between the fatty acids, fatty acid sugar diesters and monoester spectra are subtle and can be explained more by analyzing intensity and ratio of particular signals than appearance of additional ones. All the tested SFAE specimens showed the presence of stretching vibrations at 1725–1735 cm\(^{-1}\) (ester bonds), stretching vibrations in the range of 3000–3500 cm\(^{-1}\) (sugar ring -OH groups) and stretching vibrations in the range of 2800 to 3000 cm\(^{-1}\) (-CH\(_2\) aliphatic chain). All these spectra showed great similarity to the spectrum of the reference sample, which was a commercially available standard of sucrose monolaurate.

Furthermore, an in-depth analysis performed by MS/MS measurements supports the obtained results from spectroscopic studies and allow for quantification of reaction yields. The SFAEs were analyzed in positive and negative modes after ionization in electrospray (ESI) where they formed different adducts (ESI+: [M + H]\(^+\); [M + Na]\(^+\); [M + K]\(^+\) and ESI-: [M – H]\(^-\); [M – Cl]\(^-\); [M – H\(_2\)O]\(^-\)). These specimens were fragmented to obtain structural fragments of SFAE molecules (Table S1 in Supplementary Materials). It was noticed that the obtained sugar esters after biocatalytic synthesis were mixtures of different mono and diesters (Table 1). For example, the lipase produced, on average, a 6:4 ratio of mono- to diesters when methyl esters of nonanoic or (R)-3-hydroxynonanoic acids were used. Interestingly, when a fluorinated version of C9 PHN monomer was used,
this proportion had changed—we observed that CalB produced 86.6% monoester with C9 PHN monomer, virtually no C9-C9 PHN diester and 12.7% of C7-C7 PHN diester. Monosaccharides, when reacted with nonmodified PHN monomers and aliphatic fatty acid esters predominantly, produced SFAE monoesters in the presence of CalB. When bulkier, fluorinated PHN monomers were used, the lipase synthesized diesters. Subsequently, the product ions with the highest intensities obtained from SFAE fragmentation in MS/MS experiments were used for quantification of the reaction yields. In general, the conversion yields obtained varied between 10.25 and 42.49% (Table 1). As a rule of thumb, glucose appeared to be the most reactive sugar in our experimental setup. We have observed that the introduction of a fluorinated moiety on a PHN monomer resulted in an averaged 2.3-fold drop in the reaction yield for monosaccharides but did not affect synthesis of lactose esters as much (1.1-fold decrease). All of these characterized SFEA mixtures were submitted for biological studies.

| Ester    | Monoester with C9 Chains [%] | Monoester with C7 Chains [%] | Diester C9 Chains [%] | Diester C7 Chains [%] | Diester C9C7 Chains [%] | Conversion after 48 h [%] |
|----------|-----------------------------|-----------------------------|-----------------------|-----------------------|-------------------------|-------------------------|
| C9-glu   | 57.8                        | -                           | 42.2                  | -                     | -                       | 17.8                    |
| C9-gal   | 99.9                        | -                           | -                     | -                     | -                       | 17.8                    |
| C9-lac   | 56.2                        | -                           | 43.8                  | -                     | -                       | 10.4                    |
| mPHN-glu | 88.1                        | 0.7                         | -                     | -                     | 11.2                    | 42.5                    |
| mPHN-gal | 38.6                        | -                           | 18.8                  | 42.7                  | -                       | 24.3                    |
| mPHN-lac | 59.4                        | -                           | 40.6                  | -                     | -                       | 12.6                    |
| F-mPHN-glu | 0.4                       | 8.5                         | 76.0                  | 10.3                  | 4.6                     | 18.9                    |
| F-mPHN-gal | -                          | -                           | -                     | 90.9                  | 9.1                     | 10.3                    |
| F-mPHN-lac | 86.6                       | 0.2                         | 0.5                   | 12.7                  | -                       | 11.0                    |

Where '-'—not present.

3.3. MTT Assay Indicating Anti-Proliferative Properties of C9, mPHN and F-mPHN Based SFAE

To understand anti-cancer effect of the sugar fatty esters, in vitro inhibitory concentrations (IC$_{50}$) of each ester in the MTT test were determined. The experiments indicated a low cytotoxicity of the referring compounds which the hydrophilic SFAE groups are made of, namely, glu, gal and lac (data not shown). Similarly, the toxicity of the SFAE’s hydrophobic molecules (i.e., nonanoic acid and its sodium salt and modified and unmodified PHN monomers (either in acidic or salt forms)) oscillated in the range of 0.23 to over 4.09 × 10$^{-3}$ mol L$^{-1}$, respectively. They were two- to fourfold higher than the IC$_{50}$ of the tested mPHN-based sugar esters. The most promising group of the potential therapeutic compounds turned out to be the esters of the PHN monomers armed with trifluoroethyl groups and also mPHN lactose ester (Table 2 and Supplementary Figure S15). In the case of F-mPHN-glu and F-mPHN-gal, the toxicity against DU145 prostate cancer cells was around 0.1 × 10$^{-3}$ mol L$^{-1}$ (after 72 h and 120 h) and 0.08-0.33 × 10$^{-3}$ mol L$^{-1}$ of F-mPHN-lac, respectively. For comparison, the IC$_{50}$ values for sodium salts of the fluorinated monomers PHN alone were 0.23 × 10$^{-3}$ mol L$^{-1}$ after 24 h and >1.84 × 10$^{-3}$ mol L$^{-1}$ after 120 h. The IC$_{50}$ values of the esters for PNT2 (control) cells were respectively: 0.93 × 10$^{-3}$ mol L$^{-1}$ for fluorinated glucose esters, 1.18 × 10$^{-3}$ mol L$^{-1}$ for galactose esters and 1.16 × 10$^{-3}$ mol L$^{-1}$ for lactose esters. Fluorinated PHN monomers alone gave this effect at more than 4.09 × 10$^{-3}$ mol L$^{-1}$ at 72 h and 1.84 × 10$^{-3}$ mol L$^{-1}$ at 120 h.
Table 2. Cytotoxicity IC$_{50}$ of SFAE determined by MTT assay.

| Time [h] | C9-glu | C9-gal | C9-lac | PHN-glu | PHN-gal | PHN-lac | F-mPHN-glu | F-mPHN-gal | F-mPHN-lac |
|---------|--------|--------|--------|---------|---------|---------|------------|------------|------------|
| DU145   | 24     | 1.32   | 1.36   | 0.92    | 0.93    | 0.75    | 0.16       | 0.10       | 0.10       |
|         | 72     | 0.66   | 0.78   | 0.84    | 0.54    | 0.50    | 0.13       | 0.10       | 0.10       |
|         | 120    | 1.32   | 1.36   | 0.96    | 0.92    | 0.61    | 0.20       | 0.10       | 0.10       |
| PNT2    | 24     | 2.49   | 2.39   | 1.71    | 1.31    | 1.26    | 0.42       | 0.18       | 0.18       |
|         | 72     | 1.11   | 1.23   | 0.92    | 1.31    | 1.26    | 0.42       | 0.18       | 0.18       |
|         | 120    | 2.05   | 2.36   | 1.74    | 1.18    | 1.84    | 0.17       | 0.93       | 1.18       |
| HTB140  | 24     | 1.47   | 1.66   | 0.62    | 1.77    | 0.97    | 0.64       | 0.09       | 0.16       |
|         | 72     | 1.32   | 1.56   | 0.92    | 1.20    | 1.22    | 0.28       | 0.09       | 0.16       |
|         | 120    | 1.13   | 1.56   | 0.81    | 1.69    | 1.50    | 0.44       | 0.37       | 0.25       |
| HaCAT   | 72     | 1.32   | 1.56   | 0.92    | 1.43    | 1.20    | 0.38       | 0.73       | 0.58       |
|         | 120    | -      | -      | -       | -       | -       | -          | 0.80       | 0.95       |
| HSF     | 72     | 1.32   | 1.56   | 0.92    | 0.61    | 0.62    | 0.45       | -          | -          |
|         | 120    | -      | -      | -       | 0.76    | 0.50    | 0.63       | 0.76       | 0.50       |

DU145—prostate cancer; PNT2—prostate epithelium—control; HTB140—human skin melanoma; HaCaT—human skin keratynocytes; HSF—human skin fibroblasts; —-not determined. Red fillings mark the lowest concentrations needed to reduce a cell population to 50% and green—the highest. Standard deviations of IC$_{50}$ values are available in Supplementary Table S2 and graphical representation contains Supplementary Figure S15.

Analyzing the effect of sugar esters based on F-mPHN against the melanoma HTB140 line after 24 and 72 h incubation, a higher effectiveness of F-mPHN-glu in antiproliferative activity (IC$_{50}$ values 0.06 and 0.09 $\times$ 10$^{-3}$ mol L$^{-1}$, respectively) than F-mPHN-gal (0.156 $\times$ 10$^{-3}$ mol L$^{-1}$) could be observed. Extending the times of incubation up to 120 h did not affect the cancer cells negatively. It caused increase of IC$_{50}$ concentrations up to 0.37 $\times$ 10$^{-3}$ mol L$^{-1}$ for F-mPHN-glu, up to 0.25 $\times$ 10$^{-3}$ mol L$^{-1}$ for F-mPHN-gal and 0.39 $\times$ 10$^{-3}$ mol L$^{-1}$ for F-mPHN-lac, respectively. In relation to the HaCaT and HSF control cells it was necessary to use about two- to eightfold fold greater concentrations of the discussed compounds, respectively. mPHN-glu showed much higher toxicity against DU145 line than their mPHN-glu and mPHN-gal counterparts and less than those having trifluorooethyl groups. The IC$_{50}$ value of mPHN-lac dropped from 0.16 $\times$ 10$^{-3}$ mol L$^{-1}$ at 24 h to 0.13 $\times$ 10$^{-3}$ mol L$^{-1}$ at 72 h to less than 0.09 $\times$ 10$^{-3}$ mol L$^{-1}$ at 120 h. mPHN-lac turned out to be less harmful to PNT2 cells because their IC$_{50}$ values decreased from at least 0.42 $\times$ 10$^{-3}$ mol L$^{-1}$ after 24 h to 0.16 $\times$ 10$^{-3}$ mol L$^{-1}$ after 120 h. Additionally, a more promising situation was not the case of melanoma cells. The IC$_{50}$ of these compounds were 0.69 $\times$ 10$^{-3}$ mol L$^{-1}$ after 24 h; 0.28 $\times$ 10$^{-3}$ mol L$^{-1}$ after 72 h and 0.43 $\times$ 10$^{-3}$ mol L$^{-1}$ after 120 h for HTB140 cells, whereas IC$_{50}$ after 72 h for control cells: HaCaT was 0.38 $\times$ 10$^{-3}$ mol L$^{-1}$ and 0.50 $\times$ 10$^{-3}$ mol L$^{-1}$ for HSF.

3.4. Cell Structures Imaging Indicate Reorganization of Intermediate Filaments in the Presence of a Selected SFAE

Three cytoskeletal elements were analyzed: actin filaments (red ladder), microtubules (green ladder) and intermediate filaments (vimentin—white; Figure 2). These fibers showed morphology characteristic for normal cells grown on glass [32]. The actin filaments were thick and rarely distributed and the microtubules were seen as thick and distinctly separated beams. It was also noticed (Figure 2b) that the presence of the investigated SFAE caused some changes in the other components of the cytoskeleton: actin and microtubules. In the case of microscopic images showing the cytoskeleton, an increased presence of biodiversity pickling inside the cytoplasm can be seen, which may suggest an elevated content of depolymerized actin. On the other hand, the microtubules in cells in the presence of sugar esters show a greater density of fibers and their lower diameter. Similar changes in the cytoskeleton are often associated with the apoptosis process [33,34]. The literature shows the direct influence of the cell’s environment on the shape, dynamics and architecture of both actin and microtubule fibers [32]. However, these differences are not big enough to specify and propose any certain intracellular mechanism of interaction with the SFAE.
| F-mPHN-gluc | glue | C9-lac | mPHN-lac | lac |
|-------------|------|--------|----------|-----|

(a)

**Figure 2. Cont.**
| lac | glu | mPHN-lac | F-mPHN-glu |
|-----|-----|----------|------------|

**Figure 2. Cont.**
Figure 2. Changes in cytoskeleton of cancer cells visualized with confocal microscopy. Microtubular network—green channel (488 nm); Actin-cytokinoskeleton—red channel (546 nm); intermediate filaments (vimentin)—white channel (excitation—far red 647 nm). Brighter areas (greater density) that can be observed in green channels indicate greater polymerization of microtubules. An increased presence of biodiverse pickling inside the cytoplasm can be seen in red channels suggests an elevated content of depolymerized actin: (a) DU145 after 48 h of incubation; (b) High resolution images of DU145 after 48 h of incubation; (c) High resolution images of HTB140 after 48 h of incubation.
Analysis of cell nuclei shape provided information about their condition. Using image analysis algorithms their roundness was determined for each cell individually (Figure 3). For DU145 cells (Figure 3a) after the first 24 h, the roundness of nuclei was in the range of 0.6–0.9, which is characteristic for normal cells in standard culture on glass medium [35]. After 48 h no significant changes in nuclei shapes of tested cells did not appear. Only in case of mPHN-lac was an increase in roundness was observed. For the cells cultured in C9-lac and mPHN acid, a decrease in nucleus roundness index was observed.

Figure 3. Changes of nuclei roundness based on image analysis algorithms. These small changes may indicate some reorganizations of cytoskeleton but are not typical for metastatic transition: (a) DU145; (b) HTB140.

In the case of the HTB140 cell line, the situation was different (Figure 3b). It was clearly visible that for these cells the general circularity index of the organelle was lower and in the range 0.5–0.75, which is normal for elongated melanoma nuclei and usually associated with changes in cytoskeleton architecture and focal adhesion appearance [36]. These changes correlated with subtle alterations of intermediate filaments and focal adhesion points observed in microscope (Figure 2). After the first 24 h from the start of cultivation the highest circularity index was presented by cells with C9-lac and mPHN-lac. The smallest round nuclei were found in cells cultured with glucose, galactose, mPHN and F-mPHN sodium salts. The changes of the nuclei shape caused by the compounds were more significant after the next 24 h. The changes occurred in almost all cell groups and a decrease in roundness index was observed in each case. The biggest change occurred in a presence of C9-lac esters, mPHN-lac and F-mPHN-lac.

Subcellular structures imaging brought our attention to changes of intermediate filaments. Our study focused on the analysis of adhesion points. They were observed as dot forms placed in the focal plane located between the cell body and glass surface. After 24 h, DU145 cells formed the smallest number of adhesion points in medium supplemented with mPHN-gal and mPHN sodium salt. All cells grown in F-mPHN mediums were characterized with a high number of adhesion points similar to pure glucose. After 48 h in all samples, except those containing glucose, a significant increase in the number of adhesion points was observed. The highest increase occurred in cells grown in media containing mPHN-gal and F-mPHN-glu solutions. The cells grown in medium with F-mPHN-gal showed a similar growth. This growth did not exceed the statistical significance in the rest of experimental samples. In case of HTB140 cells, no vimentin analysis was performed due to its almost complete depolymerization and lack of possibility of correct imaging. Metastases is a process associated with the migration of cancer cells in the body.
Its reduction may minimize this harmful phenomenon. An increase in the number of adhesion points (Figure 4) may indicate that selected compounds cause cancer cells to bond more strongly to the substrate or to the glass surface and thus their migration may be limited [37]. On the other hand, these observations may indicate an increasing intensity of the attachment points production allowing the cells to migrate [38]. In order to verify which of these processes was more likely in our case, transmigration tests were carried out and proliferated cells were counted.

3.5. Inhibition of Transmigration Caused by C9, mPHN-lac and mPHN-glu

The transmigration test was a model experiment that was performed to illustrate the ability of cells to transmigration through a microporous membrane, where the pores mimic chinks between epithelial cells. Cancer cells are able to penetrate the tissues and migrate through the walls of blood vessels into the vascular system, which is referred to as epithelial to mesenchymal transition [39]. This process allows cells to populate new niches in other tissues, creating metastases. The key issue was to learn whether the cancer cells migrate in a medium supplemented with the investigated SFAE below the IC$_{50}$ values, and if yes, whether they are able to proliferate actively after the transition process. Therefore, transmigration values obtained after 96 h for the cancer cells treated with tested compounds were checked. In parallel, the proliferation of cells with the tested compounds was examined.

The results presented in Figure 5 are the ratios of transmigration to proliferation from the experimental conditions (from tested SFAE compounds at 0.0625 mg mL$^{-1}$ concentration) in relation to the same ratios of the controls (glu, gal and lac, respectively at the same concentrations). Transmigration rates above 1.0 (100%) mean that the transmigration is enhanced, while rates below 1.0 mean that the total transmigration is inhibited by the tested compounds.
Figure 5. Transmigration assay of cancer cells in a presence of the investigated SFAE measured after 96 h. An increase in the ratio of proliferated cells after passing through the inserts, caused by the SFAE, may indicate that tested compounds could promote metastasis (at concentrations below the IC$_{50}$). A decrease in this ratio may indicate lack of such effect. (a) DU145; (b) HTB140. Figure 5 shows that the concentration of 0.0625 mg mL$^{-1}$ of mPHN-lac present in the culture medium reduced transmigration of DU145 cells in 96 h by 40%, mPHN-glu ester reduced this ability by 17%, whereas C9-lac by 25% and F-mPHN-glu by 7%. The rest of compounds had no significant effect or in case of mPHN-gal and fluorinated esters even increased the cell’s ability of transmigration up to 22 to 24%. All compounds except mPHN-lac and c9-lac enhanced the transmigration of HTB140 cells from 6% (F-mPHN salt) even to 55% (F-mPHN-glu), respectively (Figure 5b). The mPHN-lac ester and the C9-lac ester decreased this factor by 22% and 16%, respectively. These data suggest that lactose esters inhibit transmigration of either prostate cancer and melanoma cells below IC$_{50}$ concentrations. Moreover, presence of either not modified and modified mPHN component in the sugar esters affected positively on transmigration process below IC$_{50}$ values.

4. Discussion

Analysis of SFAE composition basing on MS/MS detections (Table 1) confirmed the number of monomers attached to the sugar molecule impacts the quantity of alkyl halides introduced into the ester structure. The amount of hydrophobic chains attached to a sugar is determined by the lipase specificity and the conditions of the enzymatic reaction. As shown by the MTT results and reported by others, each of these modifications can have a significant effect on the cytotoxicity of the final SFAE. Synthesized sugar esters based on nonanoic acid, unmodified and modified mPHN turned out to affect DU145 and HTB140 cancer cells. The IC$_{50}$ values determined by MTT tests were two to four times lower than in cells treated by the control compounds (C9, mPHN, F-mPHN, glu, gal and lac ranged from 0.23 to over 0.41 × 10$^{-3}$ mol L$^{-1}$). At the same time, our SFAEs were less toxic towards the healthy cell lines (PNT2, HaCAT, HSF) with the cytotoxic concentrations being eightfold higher than these used to eliminate the cancer lines (from 0.17 to 2.4 × 10$^{-3}$ mol L$^{-1}$, respectively). The range of these concentrations corresponds with the available literature data on the antiproliferative properties of other sugar esters,
especially those having the same number of carbon atoms in hydrophobic part of the molecule [15].

From the experimental data gathered it was evidenced that type and quantity of the monomers attached to the sugar molecule by the lipase, and also the type of sugar used, both have impact on the biological behavior of SFAE. Based on the UHPLC-MS/MS analysis of the compositions of each synthesized SFAE, together with the corresponding IC_{50} values, the structure–toxicity relations can be discussed. For example, C9-glu and C9-lac were composed of similar ratios of monoesters to diesters but exhibited different cytotoxicity levels towards tested cancer lines. That observation may suggest that the kind of sugar used (mono- vs. disaccharide) has a greater influence on the anticancer properties of SFAE when the same hydrophobic chain is considered. A similar pattern was observed when mPHN-based SFAE were tested, however the presence of the hydroxyl group on the aliphatic chain of SFAE resulted in the increased antiproliferative character of these sugar esters. Other studies report an important correlation in the level of cytotoxicity and the chain length of the hydrophobic component [30,35]. For example, the IC_{50} of an octanoic acid glucose ester against Jurkat (Human T-cell leukemia) was $0.12 \times 10^{-3}$ mol L$^{-1}$, whereas the 16 carbon atoms counterpart was as low as $0.02 \times 10^{-3}$ mol L$^{-1}$. This suggests that in future research it will be beneficial to screen longer fatty acid mixtures originating from polyhydroxyalkanoates for their potential in modulating the cytotoxicity of synthesized SFAEs.

The introduction of trifluoroethyl groups into mPHN further increased the cytotoxicity of the glucose and galactose esters. Interestingly, this modification did not have such a great effect on the lactose-based SFAE when compared to C9-lac or mPHN-lac compounds. It is known from the literature that nonspecific modifications of the aliphatic chain of SFAE by substitutions of hydrogen atoms by halides may further reduce the biological activity of the molecule (e.g., decrease of the glucose ester’s cytotoxicity to over $0.20 \times 10^{-3}$ mol L$^{-1}$), thus suggesting that a plan for manipulation of cytotoxicity of the SFAE presented in this work is promising for potential drug designing process.

Having examined the cytotoxicity of SFAE, we looked at the subcellular structures of the assayed cell lines after their exposition to the tested compounds below their IC_{50} concentrations. Esters (especially these based on lactose) interacted to some extend with intermediate pillars, in particular with vimentin (Figure 2—white channel), which was manifested by a minor increase in the number of cluster points after 48 h exposure to all of the tested compounds (Figure 4). In the literature, there is scarce information on SFAE interaction with the cytoskeleton. However preliminary conclusions can be drawn from observations of polyethylene glycol inhibition of polymerization/depolymerization of microtubules [40] or interactions of gallic acid-based glycoconjugates that target tubulin and its colchicine binding site [41]; that may in future help to explain antiproliferative properties of PHA-based SFAE. Nuclei shape and number of adhesion points may provide information about potential metastatic stages. Therefore, we have conducted microscopic observations of these structures. There were minimal changes in the roundness of the cell’s nuclei over a period of 24–48 h that may indicate that all of the tested SFAE did not affect these organelles significantly while treating them below the IC_{50} concentrations (Figure 3). In addition, no significant differences were seen in the amounts of adhesion points between treated and untreated cells. Our survey showed decrease in transmigration of DU145 and HTB140 cells in most of the tested compounds, with the exception of these containing fluorine atoms. This phenomenon may be associated with disturbances in the cytoskeleton architecture, however it requires additional analysis of signaling pathways related to the cytoskeleton and cell movement at the molecular levels [41]. Altogether, and keeping in mind the relatively high cytotoxicity of SFAE (Table 2), we can assume that the synthesized sugar esters will not promote metastasis.
5. Conclusions

Despite relatively high IC\textsubscript{50} values (0.06–0.17 × 10\textsuperscript{-3} mol L\textsuperscript{-1}) of the synthesized SFAEs in comparison to commonly used chemotherapeutics, the studied compounds can compete with other SFAEs already described in the literature. Their contribution in drug designing process may rely on either using the SFAE as potentially active substances or as supporting therapeutics. These PHA-based surfactants may form microemulsions or self-microemulsifying drug delivery system (SMEDDS), which may help to stabilize and distribute commercially used medicines for cancer treatment or gene therapy; thus, SFAE-based carriers could co-work with chemotherapeutics by their own cytotoxic properties [42-44]. However, antimetastatic properties of our SFAE require further investigations due to their visible influence on cytoskeleton and cell intermediate filaments [41]. Finally, the panel of tested cell lines in the cytotoxicity experiments should be extended to include other lines that may be more sensitive to the synthesized compounds. In summary, the data contained within this manuscript are benchmarks for future studies related to the creation of SMEDDS based on synthetized SFAE for targeted anticancer therapies.

6. Patents

The work presented in this manuscript is a part of a Polish patent application number P.437233 “Use of sugar esters of fatty acids, with an acid component as a mixture of monomers derived from bacterial polyhydroxyoctanoate-co-heptanoate, to inhibit tumour cell proliferation in the treatment and prevention of diseases” submitted on 8 March 2021.

Supplementary Materials: Supplementary Materials can be found at https://www.mdpi.com/article/10.3390/ijms22137238/s1.

Author Contributions: Conceptualization. M.G.; methodology. W.S., D.W., T.W. and J.S.; validation. W.S., D.W., T.W. and J.S.; formal analysis. W.S. and D.W.; investigation. W.S., D.W., T.W. and E.J.; resources. M.G., A.J.B. and F.J.P.; data curation. W.S.; writing—original draft preparation. W.S., T.W. and D.W.; writing—review and editing. M.G., A.J.B., J.S. and F.J.P.; visualization. W.S. and T.W.; supervision. M.G. and J.S.; project administration. M.G.; funding acquisition. M.G. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Science Centre, Poland [SONATA no. 2015/17/D/ST4/00514].

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article or Supplementary Materials.

Acknowledgments: We thank Zbigniew Madeja and Justyna Drukała from the Department of Cell Biology of the Jagiellonian University for providing the equipment for conducting cell tests in this publication. Wojciech Snoch acknowledges the support of InterDokMed project no. POWR.03.02.00-00-I013/16. We greatly acknowledge the joint consortium “Interdisciplinary Centre of Physical, Chemical and Biological Sciences” of ICSC PAS and INP PAS for providing access to the Agilent 1290 Infinity System with an automatic autosampler and an MS Agilent 6460 Triple Quad Detector.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study, in the collection, analyses, interpretation of data, in the writing of the manuscript.
Abbreviations

C9  nonanoic acid
C9-Me  nonanoic methyl ester
PHN  poly-(3R)-hydroxynonanoate-(3R)-hydroxyheptanoate
R3OH-C9  (3R)-hydroxynonanoate
R3OH-C7  (3R)-hydroxyheptanoate
mPHN  mixture of PHN monomers hydroxyacids: (3R)-hydroxynonanoate and (3R)-hydroxyheptanoate
mPHN-Me  mixture of PHN monomers methyl esters: (3R)-hydroxynonanoate methyl esters
R3OH-C9-Me  (3R)-hydroxynonanoate methyl esters
R3OH-C7-Me  (3R)-hydroxyheptanoate methyl esters
F-mPHN-Me  mixture of fluorinated PHN monomers: (3R)-3-(2,2,2-trifluoroethoxy)nonanoate methyl esters and (3R)-3-(2,2,2-trifluoroethoxy)heptanoate methyl esters
glu  α-D-glucopiranose
gal  β-D-galactopyranose
lac  β-D-Galactopyranosyl-(1→4)-D-glucopiranose
C9-glu  glucose nonanoic ester
C9-gal  galactose nonanoic ester
C9-lac  lactose nonanoic ester
mPHN-glu  mixture of (3R)-hydroxynonanoate glucose esters and (3R)-hydroxyheptanoate glucose esters
mPHN-gal  mixture of (3R)-hydroxynonanoate galactose esters and (3R)-hydroxyheptanoate galactose esters
mPHN-lac  mixture of (3R)-hydroxynonanoate lactose esters and (3R)-hydroxyheptanoate lactose esters
F-mPHN-glu  mixture of (3R)-3-(2,2,2-trifluoroethoxy)nonanoate glucose esters and (3R)-3-(2,2,2-trifluoroethoxy)heptanoate glucose esters
F-mPHN-gal  mixture of (3R)-3-(2,2,2-trifluoroethoxy)nonanoate galactose esters and (3R)-3-(2,2,2-trifluoroethoxy)heptanoate galactose esters
F-mPHN-lac  mixture of (3R)-3-(2,2,2-trifluoroethoxy)nonanoate lactose esters and (3R)-3-(2,2,2-trifluoroethoxy)heptanoate lactose esters

References

1. WHO Cancer. 2021. Available online: https://www.who.int/health-topics/cancer (accessed on 15 March 2021).
2. Miller, K.D.; Nogueira, L.; Mariotto, A.B.; Rowland, J.H.; Yabroff, K.R.; Alfano, C.M.; Jemal, A.; Kramer, J.L.; Siegel, R.L. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. 2019, 69, 363–385. [CrossRef] [PubMed]
3. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Dyba, T.; Randi, G.; Bettio, M.; Gavin, A.; Visser, O.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 2018, 103, 356–387. [CrossRef] [PubMed]
4. Babaei, N.; Salamci, M.U. Mixed therapy in cancer treatment for personalized drug administration using model reference adaptive control. Eur. J. Control 2019, 50, 117–137. [CrossRef]
5. Rao, S.; Sclafani, F.; Eng, C.; Adams, R.A.; Guren, M.G.; Sebag-Montefiore, D.; Benson, A.; Bryant, A.; Peckitt, C.; Segelov, E.; et al. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. J. Clin. Oncol. 2020, 38, 2510–2518. [CrossRef] [PubMed]
6. Meric-Bernstam, F.; Gonzalez-Angulo, A.M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 2009, 27, 2278–2287. [CrossRef] [PubMed]
7. Kalia, V.C.; Patel, S.K.S.; Cho, B.-K.; Wood, T.K.; Lee, J.-K. Emerging applications of bacteria as antitumor agents. Semin. Cancer Biol. 2021. [CrossRef] [PubMed]
8. Kovvasu, S.P.; Kunnamneni, P.; Joshi, R. Self-emulsifying Drug Delivery Systems and their Marketed Products: A Review. Asian J. Pharm. 2019. [CrossRef] [PubMed]
9. Staroń, J.; Dąbrowski, J.M.; Cichoń, E.; Guzik, M. Lactose esters: Synthesis and biotechnological applications. Crit. Rev. Biotechnol. 2018, 38, 245–258. [CrossRef]
10. El-Laithy, H.M.; Shoukry, O.; Mahran, L.G. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: Preclinical and clinical studies. Eur. J. Pharm. Biopharm. 2011, 77, 43–55. [CrossRef]
11. Liang, M.Y.; Banwell, M.G.; Wang, Y.; Lan, P. Effect of Variations in the Fatty Acid Residue of Lactose Monoesters on Their Emulsifying Properties and Biological Activities. J. Agric. Food Chem. 2018, 66, 12594–12603. [CrossRef]
12. Enayati, M.; Gong, Y.; Goddard, J.M.; Abbaspourrad, A. Synthesis and characterization of lactose fatty acid ester biosurfactants using free and immobilized lipases in organic solvents. *Food Chem.* 2018, 266, 508–513. [CrossRef]
13. Marquis, R.E.; Clock, S.A.; Mota-Meira, M. Fluoride and organic weak acids as modulators of microbial physiology. *FEMS Microbiol. Rev.* 2003, 26, 493–510. [CrossRef]
14. Lucarini, S.; Fagioli, L.; Campana, R.; Cole, H.; Duranti, A.; Baffone, W.; Vlasaliu, D.; Casetti, L. Unsatuated fatty acids lactose esters: Cytotoxicity, permeability and antimicrobial activity. *Eur. J. Pharm. Biopharm.* 2016, 107, 88–96. [CrossRef]
15. Lucarini, S.; Fagioli, L.; Cavanagh, R.; Liang, W.; Perinelli, D.R.; Campana, M.; Stolnik, S.; Lam, J.K.W.; Casetti, L.; Duranti, A. Synthesis, structure–activity relationships and in vitro toxicity profile of lactose-based fatty acid monoesters as possible drug permeability enhancers. *Pharmaceutics* 2018, 10, 81. [CrossRef]
16. Ferrer, M.; Perez, G.; Plou, F.J.; Castell, J.V.; Balleseros, A. Antitumour activity of fatty acid maltoltriose esters obtained by enzymatic synthesis. *Biotechnol. Appl. Biochem.* 2005, 42 Pt 1, 35–39. [CrossRef]
17. Okabe, S.; Suganuma, M.; Tada, Y.; Ochiai, Y.; Sueoka, E.; Kohya, H.; Shibata, A.; Takahashi, M.; Mizutani, M.; Matsuoka, T.; et al. Disaccharide esters screened for enhancement of tumor necrosis factor-α release are new anti-cancer agents. *Jpn. J. Cancer Res.* 1999, 90, 669–676. [CrossRef]
18. Yanagita, R.C.; Kobashi, K.; Ogawa, C.; Ashida, Y.; Yamaashi, H.; Kawanami, Y. Anti-proliferative activity of 6-O-acyl-D-allose against the human leukemia MOLT-4F cell line. *Biosci. Biotechnol. Biochem.* 2017, 81, 190–194. [CrossRef]
19. Kasuya, M.C.Z.; Ito, A.; Cusi, R.; Sato, T.; Hatanaka, K. Cellular uptake and saccharide chain elongation of “fluoro-amphilphilic” glycosides. *Chem. Lett.* 2005, 34, 856–857. [CrossRef]
20. Yerien, D.E.; Bonesi, S.; Postigo, A. Fluorination methods in drug discovery. *J. Fluor. Chem.* [PubMed] 2016, 14, 8398–8427. [CrossRef]
21. Murphy, C.D.; Sandford, G. Recent advances in fluorination techniques and their anticipated impact on drug metabolism and toxicity. *Expert Opin. Drug Metab. Toxicol.* 2015, 11, 589–599. [CrossRef]
22. Gál, B.; Buczer, C.; Burns, N.Z. Chiral alkyl halides: Underexplored motifs in medicine. *Mar. Drugs* 2016, 14, 206. [CrossRef] [PubMed]
23. Zhou, J.; Gupta, K.; Aggarwal, S.; Aneja, R.; Chandra, R.; Panda, D.; Joshi, H.C. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. *Mol. Pharmacol.* 2003, 63, 799–807. [CrossRef] [PubMed]
24. Isanbor, C.; Hagan, D.O. Fluorine in medicinal chemistry: A review of anti-cancer agents. *J. Fluor. Chem.* 2006, 127, 303–319. [CrossRef]
25. Kirk, K.L. Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules. *J. Fluor. Chem.* 2006, 127, 1013–1029. [CrossRef]
26. Duci, S.; Forrest, R.; Hadfield, J.A.; Kendall, A.; Lawrence, N.J.; McGown, A.T.; Rennison, D. Potent antimicrobial and cell growth inhibitory properties of substituted chalcones. *Bioorg. Med. Chem. Lett.* 1998, 8, 1051–1056. [CrossRef]
27. Li, X.; Turánek, J.; Knötigová, P.; Kudláčková, H.; Mašek, J.; Parkin, S.; Rankin, S.E.; Knutson, B.L.; Lehmler, H.J. Hydrophobic tail length, degree of fluorination and headgroup stereochemistry are determinants of the biocompatibility of (fluorinated) carbohydrate surfactants. *Colloids Surf. B Biointerfaces* 2009, 73, 65–74. [CrossRef]
28. Kalia, V.C.; Singh Patel, S.K.; Shanmugam, R.; Lee, J.K. Polyhydroxyalkanoates: Trends and advances toward biotechnological applications. *Bioresour. Technol.* 2021, 326, 124737. [CrossRef]
29. Snoch, W.; Stepien, K.; Prajsnar, J.; Staroń, J.; Szaleniec, M.; Guzik, M. Influence of chemical modifications of polyhydroxyalkanoate-derived fatty acids on their antimicrobial properties. *Catalysts* 2019, 9, 510. [CrossRef]
30. Sofińska, K.; Barbasz, J.; Witko, T.; Dryzek, J.; Harazka, K.; Witko, M.; Kryściak-Czerwenka, J.; Guzik, M. Structural, topographical, and mechanical characteristics of purified polyhydroxyoctanoate polymer. *J. Appl. Polym. Sci.* 2019, 136, 136. [CrossRef]
31. Guzik, M.; Witko, T.; Steinbichel, A.; Wojnarowska, M.; Sołtysik, M.; Wawak, S. What Has Been Trending in the Research of Polyhydroxyalkanoates? A Systematic Review. *Front. Bioeng. Biotechnol.* 2020, 8, 35–39. [CrossRef]
32. Witko, T.; Solarz, D.; Feliksik, K.; Rajfur, Z.; Guzik, M. Cellular architecture and migration behavior of fibroblast cells on polyhydroxyoctanoate (PHO): A natural polymer of bacterial origin. *Biopolymers* 2019, 110, e23324. [CrossRef]
33. Povea-Cabello, S.; Oropesa-Avila, M.; de la Cruz-Ojeda, P.; Villanueva-Paz, M.; de la Mata, M.; Suárez-Rivero, J.M.; Álvarez-Cordoba, M.; Villalón-García, I.; Cotán, D.; Ybot-González, P.; et al. Dynamic reorganization of the cytoskeleton during apoptosis: The two coffins hypothesis. *Int. J. Mol. Sci.* 2017, 18, 2393. [CrossRef]
34. Gourlay, C.; Ayscough, K. The actin cytoskeleton in ageing and apoptosis. *FEBS Yeast Res.* 2005, 5, 1193–1198. [CrossRef]
35. Ankam, S.; Teo, B.K.K.; Pohan, G.; Ho, S.W.L.; Lim, C.K.; Yi, E.K.F. Temporal Changes in Nucleus Morphology, Lamin A/C and Histone Methylation During Nanotopography-Induced Neuronal Differentiation of Stem Cells. *Front. Bioeng. Biotechnol.* 2018, 6, 6. [CrossRef]
36. Lennerz, J.; Schönlin, M.; Weissinger, S.; Brandes, A.; Herrmann, M.; Möller, P. A nuclear circularity-based classifier for diagnostic distinction of desmoplastic from spindle cell melanoma in digitized histological images. *J. Pathol. Inform.* 2014, 5, 40. [CrossRef]
37. Wang, B.; Hu, Q.; Wan, T.; Yang, F.; Cui, L.; Hu, S.; Gong, B.; Li, M.; Zheng, Q.C. Porous Lactose-Modified Chitosan Scaffold for Liver Tissue Engineering: Influence of Galactose Moieties on Cell Attachment and Mechanical Stability. *Int. J. Polym. Sci.* 2016, 2016, 2862738. [CrossRef]
38. Carolina, N.; Carolina, N.; Hill, C.; Carolina, N. Cell Migration. *Compr Physiol.* 2015, 2, 2369–2392. [CrossRef]
39. Liu, C.Y.; Lin, H.H.; Tang, M.J.; Wang, Y.K. Vimentin contributes to epithelial-mesenchymal transition ancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. *Oncotarget* 2015, 6, 15966–15983. [CrossRef]

40. Bachand, G.D.; Jain, R.; Ko, R.; Boussein, N.F.; Vandelinder, V. Inhibition of Microtubule Depolymerization by Osmolytes. *Biomacromolecules* 2018, 19, 2401–2408. [CrossRef]

41. Upadhyaya, K.; Hamidullah; Singh, K.; Arun, A.; Shukla, M.; Srivastava, N.; Ashraf, R.; Sharma, A.; Mahar, R.; Shukla, S.K.; et al. Identification of gallic acid based glycoconjugates as a novel tubulin polymerization inhibitors. *Org. Biomol. Chem.* 2016, 14, 1338–1358. [CrossRef]

42. Zhao, Y.; Liu, A.; Du, Y.; Cao, Y.; Zhang, E.; Zhou, Q.; Hai, H.; Zhen, Y.; Zhang, S. Effects of sucrose ester structures on liposome-mediated gene delivery. *Acta Biomater.* 2018, 72, 278–286. [CrossRef] [PubMed]

43. Guan, Y.; Chen, H.; Zhong, Q. Nanoencapsulation of caffeic acid phenethyl ester in sucrose fatty acid esters to improve activities against cancer cells. *J. Food Eng.* 2019, 246, 125–133. [CrossRef]

44. Richard, J. Challenges and opportunities in the delivery of cancer therapeutics. *Ther. Deliv.* 2011, 2, 107–121. [CrossRef] [PubMed]